Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Jan;50(1):148-55.
doi: 10.1128/AAC.50.1.148-155.2006.

In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections

Affiliations

In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections

Ellie J C Goldstein et al. Antimicrob Agents Chemother. 2006 Jan.

Abstract

The in vitro activity of moxifloxacin against 923 recent anaerobic isolates obtained from pretreatment cultures in patients with complicated intra-abdominal infections was studied using the CLSI M11-A-6 agar dilution method. Moxifloxacin was active against 87% (96 of 110) Bacteroides fragilis strains at < or = 1 microg/ml and 87% (79 of 90) B. thetaiotaomicron strains at < or = 2 microg/ml. Species variation was seen, with B. uniformis, B. vulgatus, Clostridium clostridioforme, and C. symbiosum being least susceptible and accounting for most of the resistant isolates; excluding the aforementioned four resistant species, 86% (303 of 363) of Bacteroides species isolates and 94% (417 of 450) of all other genera and species were susceptible to < or = 2 microg/ml of moxifloxacin. Overall, moxifloxacin was active against 763 of 923 (83%) of strains at < or = 2 microg/ml, supporting its use as a monotherapy for some community-acquired intra-abdominal infections.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Ackermann, G., R. Schaumann, B. Pless, et al. 2000. Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria. Eur. J. Clin. Microbiol. Infect. Dis. 19:228-232. - PubMed
    1. Aldridge, K. E., and D. S. Ashcraft. 1997. Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes. Antimicrob. Agents Chemother. 41:709-711. - PMC - PubMed
    1. Aldridge, K. E., D. Ashcroft, M. O'Brien, and C. V. Sanders. 2003. Bacteremia due to Bacteroides fragilis group: distribution of species, β-lactamase production, and antimicrobial susceptibility patterns. Antimicrob. Agents Chemother. 47:148-153. - PMC - PubMed
    1. Bauernfeind, A. 1997. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J. Antimicrob. Chemother. 40:639-651. - PubMed
    1. Dalhoff, A., U. Petersen, and R. Endermann. 1996. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy 42:410-425. - PubMed

Publication types

MeSH terms

LinkOut - more resources